Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

mpany may not be able to monetize any of its assets. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                      Media
    info@peregrineinc.com                          Jennifer Anderson
    (800) 987-8256                                 (212) 918-4642



                           --Financial Tables to Follow--

    PEREGRINE PHARMACEUTICALS, INC.

    CONSOLIDATED BALANCE SHEETS
    AS OF APRIL 30, 2009 AND 2008

                                                   2009         2008
                        
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... (PRWEB) September 02, 2014 - Molecular ... as a class of diagnostic test that analyzes proteins ... nucleic acids and proteins that belong to individual patients ... health condition, or risk of developing a specific disease. ... known as (MDx) evaluating the new class of diagnostic ...
(Date:9/2/2014)... A little white pill may help scientists learn ... than their peers, even if their lungs are relatively ... marketed as Revatio to treat pulmonary hypertension and ... cocktail of over-the-counter antioxidants will help them identify the ... difficult for these patients. , "We want to ...
(Date:9/2/2014)... The Society of Nuclear Medicine and Molecular Imaging (SNMMI) ... SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 ... the late Kanji Torizuka, MD, PhD, is designed to ... nuclear medicine and molecular imaging for Japanese physicians in ... "SNMMI is proud to sponsor the Wagner-Torizuka Fellowship. This ...
(Date:9/2/2014)... 2014 Vertebral invasive compression fractures called ... vertebrae in our spine suffers crack or gets deformed. ... in people with osteoporosis or low bone density. Though ... forms of metastatic tumors and extensive trauma such as ... can also lead to such fractures. , The placement ...
(Date:9/2/2014)... 02, 2014 Concorde Career College ... to receive the 2014 Excellence in Community Service ... and Colleges (ACCSC). , Every year, the Accrediting ... members who make outstanding contributions in their local ... for the scope and impact of the community ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 2Health News:An Overview of the Minimally Invasive Vertebral Compression Fracture Repair Market by Transparency Market Research 3Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2
... HealthDay Reporter , TUESDAY, July 27 (HealthDay News) -- ... lost? Seeking out the right Web site might help, a ... logged on to a specially designed Internet site for weight maintenance ... loss than people who logged on less often, new research finds. ...
... HealthDay Reporter , MONDAY, July 26 (HealthDay News) -- An ... to help severely disabled people play computer games, express themselves ... experimental "sniff controller" takes advantage of the fact that cranial ... still able to send messages to the soft palate (the ...
... (BRONX, NY) For the third time in four months, ... the National Institutes of Health (NIH) has awarded Albert Einstein ... at helping people infected with multidrug-resistant tuberculosis (MDR-TB). ... The latest awardee Neel Gandhi, M.D. , assistant ...
... that patients often exhibit a significant decrease in weight and body ... The study is the first of its type to correct ... between the ages of 29 to 73 years. The study ... of 196 Mount Sinai patients who had knee or hip replacement ...
... What,s a baseball game or a football game or a ... offer a staggering array of food from appetizers to desserts. But ... beer. A special news media briefing and reception will focus ... 240th National Meeting & Exposition , which be held here ...
... 2010) A major research company affiliated with the ... is partnering with the University of Colorado,s Anschutz Medical ... discoveries from the laboratory to the patient. CPC, formally ... the University Physicians Incorporated building across the street from ...
Cached Medicine News:Health News:To Help Keep Weight Off, Turn to the Web 2Health News:To Help Keep Weight Off, Turn to the Web 3Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 2Health News:Sniffing Device Allows Disabled to Write, Run Wheelchairs 3Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Many knee and hip replacement patients experience weight decrease after surgery 2Health News:Special news media briefing and reception during American Chemical Society national meeting 2Health News:University of Colorado joins forces with major research affiliate 2
(Date:9/2/2014)... Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... in the U.S. and XIAPEX ® in the ... will present at the following upcoming investor conferences. ... Renshaw 16 th Annual Global Investment Conference ( ... at 9:10 a.m. EDT , Aegis Capital 2014 ...
(Date:9/2/2014)... 2, 2014  MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... a randomized Phase II clinical trial of its ... azacitidine in patients with previously untreated intermediate-2 or ... study enrolled a total of 108 patients with ...
(Date:9/2/2014)... SAN ANTONIO , Sept. 2, 2014 /PRNewswire/ ... private medical technology company focused on innovating lifesaving ... announced the appointment of Dr. Gabriele Niederauer ... President and CEO. Following the recent closure of ... CE Mark for the Surfacer™ Inside-Out Access Catheter ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO 2
... Inc. ( www.hydrocision.com ), a privately held medical ... majority of the Company by new investors, led ... Omega Funds. HydroCision is the developer, manufacturer, and ... allows discectomy and interbody fusion procedures to be ...
... CITY, Sept. 15 Amedica Corporation, a spinal and ... nitride (SiN) ceramic technologies, announced today that it has ... disc replacement (TDR) technology that features the use of ...  U.S. Patent No. 7,758,646 B2 and U.S. Patent No. ...
Cached Medicine Technology:HydroCision Announces New Investment to Accelerate Growth of Novel Fluidjet Technology for Minimally Invasive Spine Surgery 2Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: